TEVA UK HOLDCO 1 LIMITED
Get an alert when TEVA UK HOLDCO 1 LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-09-30 (in 4mo)
Last made up 2025-09-16
Watchouts
None on the register
Accounts
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Azets Audit Services Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors consider that preparing the financial statements on a going concern basis is appropriate due to the continued financial support of Teva Pharmaceuticals Europe B.V., a fellow group company. The directors have received confirmation from Teva Pharmaceuticals Europe B.V. that it has pledged its continuing support for a minimum of 12 months from the date of signing these financial statements.”
Group structure
- TEVA UK HOLDCO 1 LIMITED · parent
- Teva UK Holdco 2 Limited 100%
- Teva UK Holdco 3 Limited 100%
- Orvet UK 100%
- Teva Holdco US, Inc. 100%
- Anda Holdco Corp. 100%
- Anda Marketing, Inc. 100%
- Anda Pharmaceuticals, Inc. 100%
- Anda, Inc. 100%
- Anda Puerto Rico Inc. 100%
- Teva API, Inc. 100%
- Teva Digital Health, Inc. 100%
- Teva Pharmaceuticals USA, Inc. 100%
- Actavis Holdco US, Inc. 100%
- Actavis Laboratories UT, Inc. 100%
- Actavis Puerto Rico Holdings Inc. 100%
- Coventry Acquisition, LLC 100%
- Actavis Pharma, Inc. 100%
- Actavis Pharmaceuticals NJ, Inc. 100%
- Watson Laboratories, Inc [Connecticut] 100%
- Watson Pharma Private Limited 100%
- Andrx LLC 100%
- Actavis Laboratories FL, Inc. 100%
- Watson Management Corporation 100%
- Watson Therapeutics, Inc. 100%
- Circa Pharmaceuticals West, Inc. 100%
- Royce Research and Development Limited Partnership I 100%
- Watson Laboratories, Inc. [Nevada] 100%
- Actavis US Holding LLC 100%
- Actavis LLC 100%
- Actavis Elizabeth LLC 100%
- Actavis Kadian LLC 100%
- Actavis Mid Atlantic LLC 100%
- Actavis South Atlantic LLC 100%
- Actavis Totowa LLC 100%
- Cobalt Laboratories LLC 100%
- Watson Laboratories, LLC 100%
- Watson Manufacturing Services, Inc. 100%
- Watson Pharmaceuticals (Asia) Limited 100%
- Changzhou Siyao Pharmaceuticals Co., Ltd. 25%
- Watson Pharmaceuticals (China) Limited 100%
- Med All Enterprise Consulting (Shanghai) Co., Limited 100%
- WP Holdings, Ltd. 100%
- Watson Pharmaceuticals International, Limited 100%
- ANTARES PHARMA INC. 1%
- Auspex Pharmaceuticals LLC 100%
- Barr Pharmaceuticals, LLC 100%
- Barr Laboratories LLC 100%
- Barr International Services, Inc. 100%
- PLIVA, Inc. 100%
- Odyssey Pharmaceuticals, Inc. 100%
- Teva Women's Health, LLC 100%
- Teva Sales and Marketing, Inc. 100%
- Cupric Holding Co. LLC 100%
- Cephalon, LLC 100%
- Anesta LLC 100%
- Cephalon Development Corporation 100%
- Cephalon Clinical Partners, LP 100%
- CIMA Labs, Inc. 100%
- East End Insurance, Ltd. 100%
- Gecko Health Innovations, Inc. 100%
- IVAX LLC 100%
- IVAX Pharmaceuticals Mexico, S.A. de C.V. 100%
- IVAX (Bermuda) Ltd. 100%
- IVAX Argentina S.A. 100%
- IVAX Far East, Inc. 100%
- China National Pharmaceutical Logistics Corp. LTD 10%
- IVAX Holdings C.I. 100%
- Laboratorio Chile, S.A. 100%
- LBC International Corp. 100%
- Pharmatrade S.A. 100%
- Teva Pharmaceuticals Colombia SA S 100%
- TEVA INVERSIONES Y EXPORTACIONES SPA 100%
- IVAX Pharmaceuticals, LLC 100%
- Doral Manufacturing, Inc. 100%
- Goldline Laboratories, Inc. 100%
- IVAX Pharmaceuticals NV, LLC 100%
- IVAX Pharmaceuticals Caribe, Inc. 100%
- IVAX Specialty Chemicals Sub, LLC 100%
- Maancirkel Holding B.V. 100%
- Inmobiliaria Lemery, S.A. de C.V. 100%
- Patient Services and Solutions, Inc. 100%
- TAPI Puerto Rico, Inc. 100%
- Teva Branded Pharmaceutical Products R&D LLC 100%
- Teva Neuroscience, Inc. 100%
- Teva Pharmaceuticals Panama, S.A. 100%
- Teva Respiratory, LLC 100%
- IVAX Laboratories Puerto Rico, Inc. 100%
- TEVA Uruguay S.A. 100%
- Labrys Biologics, Inc. 100%
- MicroDose Therapeutx, Inc. 100%
- Sicor Inc. 100%
- Rakepoll Holding B.V. 100%
- Lemery S.A. de C.V. 100%
- Sicor de México S.A. de C.V. 100%
- TEVA Pharmaceuticals Mexico S.A. de C.V. 100%
- UAB Teva Baltics 100%
- Teva Parenteral Medicines, Inc. 100%
- Teva Biopharmaceuticals USA, Inc. 100%
- Teva Pharmaceutical Finance Company, LLC 100%
- Teva Pharmaceutical Finance IV, LLC 100%
- Teva Pharmaceutical Finance Netherlands III B.V. 100%
- Teva Pharmaceutical Finance V, LLC 100%
- Teva Pharmaceutical Finance VI, LLC 100%
- Teton Pharmaceuticals, LLC 100%
- GeminX Pharmaceuticals Canada, Inc. 100%
- Corporacion Medco CA 100%
- Schein Pharmaceuticals Bermuda Limited 100%
- Representaciones E Investigaciones Medicas SA 0.009999999776482582%
- Immobiliaria Leyfe, SA de C.V. 0.009999999776482582%
- Inter Lab Pharmaceutica, SA de C.V. 0.009999999776482582%
- Watson Laboratories S. de R.L. de C.V. 50%
- New Caribe CFC 100%
- Teva API Services Mexico S de RL de C.V. 50%
Significant events
- “During March 2024, a loan receivable from a fellow group company of USD 900,000,000 with a maturity date of 24 March 2024 was extended to 24 March 2034, and loan payables to fellow group companies of USD 900,000,000 with a maturity date of 24 March 2024 were also extended to 24 March 2034.”
- “In June 2024 a series of cash transactions were undertaken to reduce the intercompany indebtedness of a number of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 1 Limited as described below: Under a subscription and settlement agreement, the company allotted to the company's holding company, Teva Finance Holding B.V., 1,101,893,094 ordinary shares of USD 1.00 each in the capital of the company at an aggregate cash subscription price of USD 1,101,893,094.26. The company then subscribed in cash for 1,101,893,094 ordinary shares of USD 1.00 each in the capital of the company's wholly-owned subsidiary, Teva UK Holdco 2 Limited, at an aggregate subscription price of USD 1,101,893,094.26.”
- “As a result of the additional cash injection into the US subsidiaries, a fellow group company repaid USD 543,914,496 of the principal amount of USD 900,000,000 which was owed to Teva UK Holdco 3 Limited under the terms of a loan agreement dated March 2024. Teva UK Holdco 3 Limited used this cash sum to repay USD 543,914,496 of the loan note of USD 900,000,000 issued by Teva UK Holdco 3 Limited and held by the company, which otherwise had a redemption date of 24 March 2034. The company then used that amount to repay in full the loan note of USD 543,914,496 issued by the company and held by another fellow group company and which otherwise also had a redemption date of 24 March 2034. As part of the agreement all intercompany balances arising on transactions that affected the company were eliminated.”
- “In August 2024 a series of cash transactions were undertaken to reduce the intercompany indebtedness of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 1 Limited as described below: Under a subscription and settlement agreement the company allotted to the company's holding company, Teva Finance Holding B.V., 457,273,600 ordinary shares of USD 1.00 each in the capital of the company at an aggregate cash subscription price of USD 457,273,600. The company then subscribed in cash for 457,273,600 ordinary shares of USD 1.00 each in the capital of the company's wholly-owned subsidiary, Teva UK Holdco 2 Limited, at an aggregate subscription price of USD 457,273,600. As part of the agreement all intercompany balances arising on transactions that affected the company were eliminated.”
- “In December 2024 the company entered into a share exchange agreement with its ultimate parent company, Teva Pharmaceutical Industries Ltd and this had the effect on Teva UK Holdco 1 Limited as described below: Under the share exchange agreement, the company allotted one ordinary share of USD 1.00 credited as fully paid to Teva Pharmaceutical Industries Ltd, in exchange for a USD 1.00 on-demand interest-free receivable and one ordinary share of USD 1.00 in the capital of the company's direct subsidiary, Teva UK Holdco 2 Limited.”
- “During 2024, the group continued a restructuring of its US operations to reduce the intercompany indebtedness of a number of the company's indirectly wholly-owned US subsidiaries, as described in the Strategic Report.”
- “In February 2025, a series of cash transactions were undertaken to reduce the intercompany indebtedness of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 1 Limited as described below: Under a subscription and settlement agreement, the company allotted to the company's holding company, Teva Finance Holding B.V., 688,906,337 ordinary shares of USD 1.00 each in the capital of the company at an aggregate cash subscription price of USD 688,906,337. The company then subscribed in cash for 688,906,337 ordinary shares of USD 1.00 each in the capital of the company's wholly-owned subsidiary, Teva UK Holdco 2 Limited, at an aggregate subscription price of USD 688,906,337. As part of the agreement all intercompany balances arising on transactions that affected the company were eliminated.”
- “During June 2025, a loan receivable from a fellow group company of USD 958,654,252 with a maturity date of 24 June 2025 was extended to 25 June 2035, and loan payables to a fellow group company of USD 958,654,252 with a maturity date of 24 June 2025 was also extended to 25 June 2035.”
- “During July 2025, a series of cash transactions were undertaken to reduce the intercompany indebtedness of the company's indirectly wholly-owned US subsidiaries and this had the effect on Teva UK Holdco 1 Limited as described below: Under a subscription and settlement agreement, the company allotted to the company's holding company, Teva Finance Holding B.V., one ordinary share of USD 1.00 in the capital of the company at a cash subscription price of USD 602,295,285. The company then subscribed in cash for one ordinary share of USD 1.00 in the capital of the company's wholly-owned subsidiary, Teva UK Holdco 2 Limited, at a cash subscription price of USD 602,295,285. The amount of the premium at which each of those shares was allotted may be subject to adjustment under the terms of that agreement. As part of the agreement all intercompany balances arising on those transactions that affected the company were eliminated.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 2 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CHARLESWORTH, Stephen Michael | Director | 2020-04-29 | Feb 1967 | British |
| COOPER, Dean Michael | Director | 2019-09-17 | Sep 1972 | British |
| KATZ, Yaron Aizik, Mr | Director | 2022-05-07 | Dec 1968 | American |
Show 2 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| HERMAN, Doron | Director | 2019-09-17 | 2022-05-07 |
| INNES, Kim | Director | 2019-09-17 | 2020-04-29 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-09-17 | Active |
Filing timeline
Last 20 of 33 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-01-21 | RP01SH01 | miscellaneous | Legacy | |
| 2025-10-06 | AA | accounts | Accounts with accounts type full | |
| 2025-09-29 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-08-14 | SH01 | capital | Capital allotment shares | |
| 2025-02-17 | SH01 | capital | Capital allotment shares | |
| 2025-01-30 | SH01 | capital | Capital allotment shares | |
| 2024-12-12 | RP04CS01 | confirmation-statement | Second filing of confirmation statement with made up date | |
| 2024-12-10 | SH01 | capital | Capital allotment shares | |
| 2024-10-21 | CS01 | confirmation-statement | Confirmation statement | |
| 2024-10-09 | AA | accounts | Accounts with accounts type full | |
| 2024-06-25 | SH01 | capital | Capital allotment shares | |
| 2023-12-14 | SH01 | capital | Capital allotment shares | |
| 2023-10-03 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-08-15 | AA | accounts | Accounts with accounts type full | |
| 2023-01-03 | AA | accounts | Accounts with accounts type full | |
| 2022-09-23 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-06-22 | SH01 | capital | Capital allotment shares | |
| 2022-05-09 | AP01 | officers | Appoint person director company with name date | |
| 2022-05-09 | TM01 | officers | Termination director company with name termination date | |
| 2021-11-12 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 5
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
Latest filed period vs the prior one
Accounts are PDF-filed; numeric extraction for this
statement type (this
accounts) is not yet supported in StatDesk. See the
Companies House filing for the underlying figures.